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Aim To determine the prevalence of muscular dystrophy 
(MD) and spinal muscular atrophy (SMA) in Croatia by use 
of multiple epidemiological tools.
Methods This epidemiological study collected data from 
three national patient registries and one database of a 
non-governmental organization (NGO) of MD and SMA 
patients. The study involved all individuals who either had 
undergone hospital treatment for MD or SMA, had consult-
ed their primary health care providers for MD- and SMA-re-
lated symptoms, were listed as disabled due to MD or SMA, 
or were members of the mentioned NGO in 2016. In order 
to prevent double entries, we created a new database of all 
living individuals, each with a unique identification num-
ber. The prevalence rates for 2016 were calculated by age 
and sex groups.
Results There were 926 patients diagnosed with MD (544 
men). Most men diagnosed with MD were in the age group 
10-19, whereas most women were in the age group 50-59. 
MD prevalence in Croatia was 22.2 per 100 000 population. 
There were 392 patients diagnosed with SMA (198 men). 
Most men with SMA were in the age group 50-59, where-
as most women were in the age group 60-69. SMA preva-
lence in Croatia was 9.3 per 100 000 population.
Conclusion SMA prevalence rate in Croatia is similar to 
SMA prevalence worldwide. However, MD prevalence rate 
is higher than worldwide estimates. This difference could 
be attributed to the fact that we could not confirm wheth-
er every patient registered in these databases actually met 
the diagnostic criteria for MD and SMA.
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Muscular dystrophies (MD) are rare disorders, affecting few-
er than 5 per 10 000 population (1). The overall worldwide 
prevalence of all types of MD was reported to be 16.1 per 
100 000 population (1 in 6200 population) (2). The com-
bined prevalence of all types of MD in the United Kingdom 
was between 19.8 and 25.1 per 100 000 person-years (3). 
However, the prevalence of specific MD types varies sig-
nificantly.
Spinal muscular atrophy (SMA) shares a number of com-
mon symptoms with MD but has a different etiology. The 
estimated incidence of SMA worldwide is 1 in 10 000 live 
births (4). Both MD and SMA are diagnosed based on clini-
cal features and increased creatine kinase levels and sub-
sequently confirmed by genetic testing and/or muscle bi-
opsy. MDs and SMA remain incurable diseases with high 
unmet medical needs.
Country- and age-specific disease prevalence is usually 
determined based on data from national and internation-
al patient registries and care and trial site registries. When 
national registries are not complete or available, there are 
other possibilities to determine epidemiologic indicators 
pertaining to a particular disease. Data on health care indi-
cators in Croatia are aggregated and statistically analyzed 
in the Croatian Institute of Public Health (CIPH) (5,6), which 
also registers individual disease cases in various patient 
registries and morbidity databases. Unambiguous link-
ing of data contained in all CIPH registries and databases 
has recently been enabled by advances in anonymization 
techniques. Moreover, CIPH has been granted access to 
data in the Central Health Information System of Croatia 
(CEZIH) database, which collects all information on prima-
ry health care provider services. This has enabled research-
ers to more accurately determine the number of MD and 
SMA patients, rather than to determine only the pattern of 
health care services they use.
There has been some research on the prevalence of specif-
ic MD in Croatia (7-9), but no data on the total prevalence 
of MD in Croatia has been published. In addition, previous 
studies conducted in Croatia involved only smaller region-
al subpopulations. When it comes to research on SMA, no 
studies have so far been conducted in Croatia. The aim of 
this study was to determine the number of patients diag-
nosed with MD and SMA in Croatia based on data con-
tained in available registries/databases. This should fa-
cilitate resource allocation in the health care system and 
provision of appropriate and timely medical care to all pa-
tients with MD and SMA.
MeTHoDS
The following data sources were used:
1) A database of all patients who underwent hospital treat-
ment in Croatia in 2016 (In-patient Statistics Form data-
base, BSO),
2) A database of all medical services provided by primary 
health care providers in Croatia in 2016 (Central Health In-
formation System of Croatia, CEZIH),
3) The Disabled Persons Registry (ROI) of the CIPH, and
4) A database of all members of the Croatian Muscular Dys-
trophy Association (SDDH).
All of the listed sources contain information on patients’ age, 
sex, and residence, as well as their personal identification 
number (OIB), which serves as a unique identifier. Addition-
ally, the CEZIH database includes the International Statisti-
cal Classification of Diseases and Related Health Problems 
(ICD) code attributed to the patient and information about 
prescribed drugs and referrals, whereas the BSO database 
contains data on the duration of hospital treatment and the 
associated ICD code. The ROI comprises information about 
the disability extent and cause (as coded in ICD). The SDDH 
database contains no additional information except the de-
mographic data and OIB identifier; in order to acquire SDDH 
membership, applicants have to provide a physician’s certifi-
cate proving the diagnosis of MD or SMA.
Data were analyzed during September 2018 in the Division 
for Public Health of the CIPH. The study involved all individ-
uals who had undergone hospital treatment for MD or SMA 
(BSO database), had consulted their primary health care 
providers for MD-related or SMA-related symptoms (CEZIH 
database), were listed as disabled due to MD or SMA in the 
ROI, or were SDDH members. The inclusion criterion was 
the diagnosis of MD or SMA as per the International Statis-
tical Classification of Diseases and Related Health Problems 
(ICD) codes G71 and G12, respectively. However, we were 
not able to confirm whether every person with ICD codes 
G71 or G12 met the diagnostic criteria for MD or SMA, re-
spectively. Deceased patients and patients with residence 
outside of Croatia (as verified in the national health insur-
ance registry) were excluded.
The data were extracted from BSO, CEZIH, ROI, and 
SDDH databases with SQL Server Management Stu-
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dio 2012 software (Microsoft, Redmond, WA, USA) and ana-
lyzed with Microsoft Excel 2010. To prevent double entries, 
all individuals were identified using their OIB number. Simi-
lar methods of quadrangulating data sources have been 
used in other studies (10,11). This study was approved by 
the Ethics Committee of the CIPH on February 1, 2018, un-
der the Registration number 381-10-18-2.
ReSulTS
There were 926 MD patients (544 or 58.7% men, sex ratio: 
1.42) (Table 1). Most men diagnosed with MD (95 individu-
als) were in the age group 10-19, whereas most women (75 
individuals) were in the age group 50-59. The overall MD 
prevalence in Croatia was 22.2 patients per 100 000 popu-
lation. The distribution of prevalence rates by age groups 
was roughly bimodal, with the greatest prevalence rates in 
the age groups 10-19 and 40-49 in both sexes. The young-
est MD patient was a male patient aged 2 years, whereas 
the oldest was a female patient aged 91.
The ROI included data on 62.6% of MD patients and SDDH 
database on 34.9% of MD patients. Other data sources 
comprised data on less than 10% of patients (Table 2). 
Moreover, the ROI included data on 518 patients not listed 
in any other data source (55.9% of the total number of MD 
patients). SDDH database included data on 323 patients 
not listed in other databases (34.9%); the proportions in 
other databases were minor (Table 3).
TaBle 1. Patients diagnosed with muscular dystrophy by sex and age groups*†
Male population Female population General population
age group (years) patients PR patients PR patients PR
0-9  44 21.1  23 11.7  67 16.5
10-19  95 42.8  41 19.5 136 31.4
20-29  83 32.6  40 16.3 123 24.6
30-39  72 24.8  40 14.2 112 19.6
40-49  70 25.1  58 20.9 128 23.1
50-59  82 27.8  75 24.3 157 26.0
60-69  60 23.4  68 23.4 128 23.4
70 +  38 18.1  37 10.6  75 13.4
Total 544 27.0 382 17.7 926 22.2
*PR – prevalence rate per 100 000 population. 
†Data on the estimated number of inhabitants in particular sex and age groups (mid-2016 estimates, published on July 27, 2017) retrieved from the 
web site of the Croatian Bureau of Statistics (https://www.dzs.hr/Hrv_Eng/Pokazatelji/Procjene%20stanovnistva.xlsx; accessed on august 27, 2018).
TaBle 2. The number of muscular dystrophy patients in individual data sources
Data source
No. (%) of muscular dystrophy patients 
in the respective database (N = 926)
No. (%) of muscular dystrophy patients 
only in the respective database (N = 926)
Disabled Persons Registry 580 (62.6) 518 (55.9)
In-patient Statistics Form database  12 (1.3)   0 (0.0)
Central Health Information System of Croatia  65 (7.0)  22 (2.4)
Croatian Muscular Dystrophy Association 345 (37.3) 323 (34.9)
TaBle 3. The number of muscular dystrophy patients in mul-
tiple data sources
Number of databases
Number (%) of muscular dystrophy 
patients in the databases (N = 926)
Two databases*
ROI + BSO  5 (0.5)
ROI + CEZIH 31 (3.3)
BSO + CEZIH  1 (0.1)
BSO + SDDH  0 (0.0)
CEZIH + SDDH  0 (0.0)
ROI + SDDH 14 (1.5)
Three databases
ROI + BSO + CEZIH  4 (0.4)
ROI + BSO + SDDH  1 (0.1)
BSO + CEZIH + SDDH  0 (0.0)
ROI + CEZIH + SDDH  6 (0.6)
Four databases
ROI + BSO + CEZIH + SDDH  1 (0.1)
*RoI – Disabled Persons Registry; BSo – In-patient Statistics Form 
database; CeZIH – Central Health Information System of Croatia; SDDH 
– Croatian Muscular Dystrophy association.
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There were 389 SMA patients (97 or 50.6% men, sex ratio: 
1.03) (Table 4). Most men diagnosed with SMA (46 individu-
als) were in the age group 50-59, whereas most women (47 
individuals) were in the age group 60-69. The overall SMA 
prevalence in Croatia was 9.3 patients per 100 000 popula-
tion. The greatest prevalence rates were observed in pa-
tients older than 50 years. The youngest SMA patients (two 
boys and one girl) were younger than one year, whereas 
the oldest patient was a female patient aged 96.
The CEZIH database included data on by far the greatest 
proportion of SMA patients, accounting for 92.8% of the 
total number of SMA patients. The SDDH database com-
prised data on 23.7%, the BSO database on 7.5%, and the 
ROI database on 74.8% of SMA patients (Table 5). The CEZ-
IH database also included data on 236 patients not listed 
in any of the other data sources (60.7% of the total number 
of SMA patients), whereas other databases accounted for a 
small proportion of SMA patients (Table 6).
DISCuSSIoN
The MD prevalence rate in Croatia is higher than the 
worldwide estimates, but similar to the prevalence ob-
tained in a systematic review from the United Kingdom 
(19.8-25.1/100 000 population). Such a high prevalence 
rate, other than by inherited factors, could be explained 
by the fact that the ICD-10 codes in the databases are not 
confirmed by a review of medical records. In a number 
TaBle 4. Patients diagnosed with spinal muscular atrophy by sex and age groups*†
Male population Female population General population
age group (years) patients PR patients PR patients PR
0-9  8  3.8   8  4.1  16  3.9
10-19  14  6.3  17  8.1  31  7.2
20-29  17  6.7  14  5.7  31  6.2
30-39  21  7.2  14  5.0  35  6.1
40-49  19  6.8  31 11.2  50  9.0
50-59  46 15.6  19  6.2  65 10.8
60-69  25  9.7  47 16.1  72 13.1
70 +  47 22.4  42 12.0  88 15.8
Total 197  9.8 192  8.9 389  9.3
*PR – prevalence rate per 100 000 population.
†Data on the estimated number of inhabitants in particular sex and age groups (mid-2016 estimates, published on July 27, 2017) retrieved from the 
web site of the Croatian Bureau of Statistics (https://www.dzs.hr/Hrv_Eng/Pokazatelji/Procjene%20stanovnistva.xlsx; accessed on august 27, 2018).
TaBle 5. The number of spinal muscular atrophy patients in individual data sources
Data source
No. (%) of spinal muscular atrophy patients 
in the respective database (N = 389)
No. (%) of spinal muscular atrophy patients 
only in the respective database (N = 389)
Disabled Persons Registry 291 (74.8)  27 (6.9)
In-patient Statistics Form database  29 (7.5)   8 (2.1)
Central Health Information System of Croatia 361 (92.8) 236 (60.7)
Croatian Muscular Dystrophy Association  92 (23.7)  20 (5.1)
TaBle 6. The number of spinal muscular atrophy patients in 
multiple data sources
Number of databases
No. (%) of spinal muscular atrophy
patients in the databases (N = 389)
Two databases
ROI + BSO  2 (0.5)
ROI + CEZIH  0 (0.0) 
BSO + CEZIH  7 (1.8)
BSO + SDDH  9 (2.3)
CEZIH + SDDH 58 (14.9)
ROI + SDDH  5 (1.3)
Three databases
ROI + BSO + CEZIH  1 (0.3)
ROI + BSO + SDDH  2 (0.5)
BSO + CEZIH + SDDH 14 (3.6)
ROI + CEZIH + SDDH  0 (0.0)
Four databases
ROI + BSO + CEZIH + SDDH  0 (0.0)
*RoI – Disabled Persons Registry; BSo – In-patient Statistics Form 
database; CeZIH – Central Health Information System of Croatia; SDDH 
– Croatian Muscular Dystrophy association.
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of cases, MD or SMA may have only been a provisional or 
working diagnosis, which was not confirmed or revised 
after further examinations or laboratory tests. This ex-
plains the discrepancies in the prevalence between dif-
ferent registries or databases. Such discrepancies stress 
the need for regular clinical audits, both in diagnostic 
and in therapeutic medical specialties, with an aim to 
improve patients’ outcomes, overall efficiency, and cost-
effectiveness. Nevertheless, regardless of whether the 
diagnosis will eventually be confirmed, if we want to ef-
ficiently manage the resources, we need to know how 
many people use the health care system under the diag-
nosis of MD or SMA.
The mean annual direct cost of MD per patient in Germany, 
Italy, United Kingdom, and United States, is approximate-
ly 10, 8, 16, and 7 times higher than the mean per-capita 
health expenditure in these countries, respectively (12,13). 
Furthermore, medical needs and health care resource use 
increase as MD progresses, with a corresponding increase 
in costs, especially after the age of 14. Higher costs in senior 
age groups are primarily attributable to a greater number 
of outpatient visits and office visits (12,13). Advances in sup-
portive care and equipment have improved patients’ surviv-
al and quality of life, however, the substantial cost of these 
services has increased the financial burden on their families 
and the health care system. Moreover, significant expenses 
incurred during diagnostic procedures also contribute to 
the overall cost of patient management in MD (14).
The total cost of health care for SMA patients in the USA 
and Germany before the introduction of nusinersen ther-
apy was US$ 957 million and € 106.2 million per year, re-
spectively (15). In Spain, the direct non-health care costs of 
SMA were higher than direct health care costs and were as-
sociated with reduced caregiver quality of life (15). This was 
predominantly related to informal caregiving, indicating 
that it is important to take into account significant hidden 
or unmeasured costs. Caring for a child with SMA can en-
tail significant financial costs associated with family care-
giving, employment constraints, caregiver burden, social 
limitations, and reduced caregiver well-being, all of which 
often remain unrecognized in quantitative studies (15).
Nusinersen therapy, approved in the USA in 2016, is the 
first efficient pharmacological treatment for SMA (16). 
Since then, nusinersen has been approved for use in nu-
merous European countries, including Croatia. However, 
its cost remains highly prohibitive, even in highly devel-
oped countries, as it amounts to up to US$ 750 000 
for the first year of treatment and US$ 375 000 for each 
subsequent year (17). A newly approved SMA medication, 
onasemnogene abeparvovec, is even more costly: applied 
as one-time treatment, a single dose costs US$ 2.125 mil-
lion (18). The costs of emerging treatment methods for 
SMA necessitate that the efficiency of existing treatments 
is investigated and possible new treatment options are 
considered.
A limitation of this study is a possible incorrect use of ICD 
code G71 and G12, designating MD and SMA, respective-
ly, in BSO and CEZIH databases. The database used in this 
study was formed by aggregating data entries found in 
multiple databases, rather than by directly examining pa-
tient histories. Consequently, it was impossible to confirm 
whether every patient registered in these databases under 
the ICD codes G71 or G12 actually met the diagnostic cri-
teria for these entities. Data from the ROI and SDDH data-
bases were confirmed by reviewing medical records, while 
the data from BSO database only refer to the principal di-
agnosis, ie, the condition that caused the hospital admis-
sion. However, since we used several registries/databases, 
these discrepancies could not have significantly affected 
the results.
Although the current SMA prevalence in Croatia is in line 
with the worldwide estimates (9.3 per 100 000 population 
vs 10.0 per 100 000 population), the MD prevalence rate 
is higher (22.2 per 100 000 population vs 16.1 per 100 000 
population). Linking anonymized data extracted from mul-
tiple databases administered by CIPH or accessible therein 
allowed us to determine relevant epidemiological indica-
tors. These are necessary for a rational management of lim-
ited human and financial resources available in the Croa-
tian health care system. Epidemiological assessments and 
consequent resource planning could be further improved 
by establishing a national registry of MD patients.
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